This Week at FDA: Speedy Drug Review Bonuses, Makary Defends Prasad, and MoreFebruary 27, 2026February 28, 2026
FDA Publishes New Product-Specific Guidances to Facilitate Generic Drug DevelopmentFebruary 26, 2026February 28, 2026
This Week at FDA: Single Pivotal Trials, FDA Reverses Course to Review Moderna Flu Vaccine, and Makary’s OTC TurnFebruary 20, 2026February 28, 2026
This Week at FDA: QMSR and PreCheck Kickoff, Makary Tries to Ease CNPV Concerns, and MoreFebruary 6, 2026February 9, 2026
This Week at FDA: CDRH Annual Report, Partial Shutdown Update, and MoreJanuary 30, 2026February 5, 2026
This Week at FDA: HHS Ends Aborted Fetal Tissue Research, PreCheck Pilot Update, and MoreJanuary 23, 2026February 5, 2026
This Week at FDA: Drug Voucher Program Hits a Snag, GOP Targets Abortion Drug, and MoreJanuary 16, 2026January 17, 2026